Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Statistics
Share Statistics
Ovid Therapeutics has 71.08M shares outstanding. The number of shares has increased by 0.18% in one year.
| Shares Outstanding | 71.08M |
| Shares Change (YoY) | 0.18% |
| Shares Change (QoQ) | 0.09% |
| Owned by Institutions (%) | 67.02% |
| Shares Floating | 56.63M |
| Failed to Deliver (FTD) Shares | 490 |
| FTD / Avg. Volume | 0.11% |
Short Selling Information
The latest short interest is 705.54K, so 0.99% of the outstanding shares have been sold short.
| Short Interest | 705.54K |
| Short % of Shares Out | 0.99% |
| Short % of Float | 1.27% |
| Short Ratio (days to cover) | 1.8 |
Valuation Ratios
The PE ratio is -2.5 and the forward PE ratio is -1.33. Ovid Therapeutics's PEG ratio is 0.05.
| PE Ratio | -2.5 |
| Forward PE | -1.33 |
| PS Ratio | 116.97 |
| Forward PS | 0.2 |
| PB Ratio | 0.97 |
| P/FCF Ratio | -1.18 |
| PEG Ratio | 0.05 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Ovid Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.32, with a Debt / Equity ratio of 0.02.
| Current Ratio | 5.32 |
| Quick Ratio | 5.32 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $24.61K |
| Profits Per Employee | $-1.15M |
| Employee Count | 23 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -88.85% in the last 52 weeks. The beta is 0.29, so Ovid Therapeutics's price volatility has been higher than the market average.
| Beta | 0.29 |
| 52-Week Price Change | -88.85% |
| 50-Day Moving Average | 0.55 |
| 200-Day Moving Average | 0.93 |
| Relative Strength Index (RSI) | 29.96 |
| Average Volume (20 Days) | 432.09K |
Income Statement
In the last 12 months, Ovid Therapeutics had revenue of 566K and earned -26.43M in profits. Earnings per share was -0.37.
| Revenue | 566K |
| Gross Profit | 566K |
| Operating Income | -61.88M |
| Net Income | -26.43M |
| EBITDA | -61.88M |
| EBIT | -61.88M |
| Earnings Per Share (EPS) | -0.37 |
Balance Sheet
The company has 26.3M in cash and 1.34M in debt, giving a net cash position of 24.96M.
| Cash & Cash Equivalents | 26.3M |
| Total Debt | 1.34M |
| Net Cash | 24.96M |
| Retained Earnings | -304.3M |
| Total Assets | 92.17M |
| Working Capital | 45.42M |
Cash Flow
In the last 12 months, operating cash flow was -55.96M and capital expenditures -71K, giving a free cash flow of -56.03M.
| Operating Cash Flow | -55.96M |
| Capital Expenditures | -71K |
| Free Cash Flow | -56.03M |
| FCF Per Share | -0.79 |
Margins
Gross margin is 100%, with operating and profit margins of -10933.75% and -4670.14%.
| Gross Margin | 100% |
| Operating Margin | -10933.75% |
| Pretax Margin | -4670.14% |
| Profit Margin | -4670.14% |
| EBITDA Margin | -10933.75% |
| EBIT Margin | -10933.75% |
| FCF Margin | -9898.76% |
Dividends & Yields
OVID does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for OVID is $3, which is 782.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $3 |
| Price Target Difference | 782.4% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -5.69 |
| Piotroski F-Score | 2 |